broad potent neutralizing antibodies african donor reveal new hiv vaccine target 
broadly neutralizing antibodies bnabs develop time hiv--infected individuals define critical epitopes hiv vaccine design using systematic approach examined neutralization breadth sera hiv--infected individuals primarily infected non-clade b viruses selected donors monoclonal antibody mab generation used high-throughput neutralization screen antibody-containing culture supernatants activated memory b cells clade a-infected african donor isolate two potent mabs target broadly neutralizing epitope epitope preferentially expressed trimeric envelope protein spans conserved regions variable loops gp120 subunit results provide framework design new vaccine candidates elicitation bnab responses 
